Drugs / CD19-CD34 CAR transduced T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04214886 | Dec 2019 → Aug 2022 overdue | B-cell adult acute lymphocytic leukemia | Loyola University | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19-CD34 CAR transduced T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04214886 ↗ |
| Modality | Cell therapy | “CD19-CD34 CAR transduced T cells are the subject's own immune cells” NCT04214886 ↗ |
| Route | Intravenous | “CD19-CD34 CAR transduced T cells will be administered IV” NCT04214886 ↗ |